# Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

> **NCT00157079** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 61 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)
- Immune Thrombocytopenic Purpura (ITP)
- Kawasaki Syndrome

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous (Human), 10%

## Key facts

- **NCT ID:** NCT00157079
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06-25
- **Primary completion:** 2003-12-16
- **Final completion:** 2003-12-16
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157079, "Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00157079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*